MBK-01

About Mikrobiomik

Mikrobiomik is a clinical-stage biotech pioneering the development of standardized, capsule-based fecal microbiota transplantation (FMT) therapies. The company has achieved a significant milestone with the European authorization of its lead product, MBK-01, for recurrent CDI under the new Substances of Human Origin (SoHO) regulation, positioning it as a leader in Spain. Its pipeline includes a Phase III trial in decompensated liver cirrhosis and a Phase II study in recurrent acute diverticulitis, targeting substantial unmet medical needs. As a private company, Mikrobiomik is transitioning towards commercialization while expanding the clinical applications of its proprietary FSPIM® technology platform.

About Mikrobiomik

Mikrobiomik is a clinical-stage biotech pioneering the development of standardized, capsule-based fecal microbiota transplantation (FMT) therapies. The company has achieved a significant milestone with the European authorization of its lead product, MBK-01, for recurrent CDI under the new Substances of Human Origin (SoHO) regulation, positioning it as a leader in Spain. Its pipeline includes a Phase III trial in decompensated liver cirrhosis and a Phase II study in recurrent acute diverticulitis, targeting substantial unmet medical needs. As a private company, Mikrobiomik is transitioning towards commercialization while expanding the clinical applications of its proprietary FSPIM® technology platform.

Therapeutic Areas